Saturday, September 02, 2023
Longaevus Technologies is excited to announce the establishment of Elastin Biosciences as an independent entity following the remarkable preclinical results achieved by three of its research programs. Longaevus Technologies is committed to advancing longevity and employs a holistic approach to combat the multiple hallmarks of aging. Its international team of distinguished scientists, hailing from prestigious universities, research institutions, and industry backgrounds, collaboratively works towards the common goal of addressing the challenges of aging.
Emerging from a year of operating in stealth mode, Elastin Biosciences, a pioneering biotech company spun off from Longaevus Technologies, has unveiled a groundbreaking discovery in the realm of elastin-related health. The core team at Elastin Biosciences, led by Chief Scientist Alexey Moskalev, Director of Research Alexander Fedintsev, and CEO Sherif Idriss, conducted successful experiments in Oxford. They identified three unique drug combinations that effectively inhibit elastin degradation and stimulate its deposition, resulting in a five-fold increase in elastin expression and an enhancement in aortic elasticity in aged mice in-vivo.
This cutting-edge research offers promising solutions for individuals affected by elastin-deficiency related diseases and holds the potential to significantly contribute to healthy longevity. As Elastin Biosciences progresses from preclinical proof of concept to the pre-IND phase, this milestone underscores the company's unwavering commitment to advancing the field of regenerative medicine. Recognizing the significance and potential of this research, Elastin Biosciences has secured an initial funding of $2.5 million. With this support, the company is preparing to launch a Series A funding round to further its mission and research initiatives.
Elastin degradation, which is associated with a range of health issues and the natural aging process, has long been a focal point in the medical community. The breakthrough achieved by Elastin Biosciences not only renews hope for those affected by elastin deficiency but also opens doors to innovative treatments aimed at improving overall health and extending lifespan.
Elastin Biosciences is now positioned to make substantial strides in regenerative medicine, heralding a new era of treatment solutions and promoting healthy aging.
